Medicare AdvantageCoverageMedium impact
MA06.001f, Apheresis Therapy
Independence Blue Cross·Hematology, Oncology, Nephrology·Medical Policy
Effective date
Mar 17, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.001f for Apheresis Therapy has been updated with changes to medical necessity criteria, medical coding, and general guidelines. The policy was notified on 12/17/2024 and becomes effective 03/17/2025.
Action Required
By March 17, 2025: Billing team must review the updated MA06.001f Apheresis Therapy policy at https://medpolicy.ibx.com for changes to medical necessity criteria and coding guidelines. Update billing procedures and documentation requirements for apheresis therapy claims to ensure compliance with new Medicare Advantage requirements.